Illustrative integration of patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) data in dose-cohort review for a phase I clinical trial
Abstract
Abstract Background This secondary analysis of a phase I clinical trial demonstrates integrated summary and visualization of Common Terminology Criteria for Adverse Events (CTCAE) data and Patient-Reported Outcomes version of the CTCAE (PRO-CTCAE) data at baseline and through the first cycle of treatment for tolerability review during dose-cohort evaluation in a phase I trial. Methods This study uses data from a phase I clinical trial of patients with relapsed or refractory acute myeloid leukemia. Through iterative feedback from clinicians and statisticians, we developed a report of cycle 1 PRO-CTCAE and CTCAE data for the first dose-level cohort. This dose-level report is intended to demonstrate reporting that would be reviewed to inform a decision about proceeding to the next dose level in a dose escalation trial. Results Cycle 1 CTCAE and PRO-CTCAE data for 4 patients enrolled in the first dose cohort are summarized as narrative and tabular summaries and visualized using swimmer and butterfly plots. In this cohort, 3/4 (75%) patients had at least one CTCAE grade 3 or higher adverse event, and all 4 (100%) patients had at least one PRO-CTCAE composite score of 3 during cycle 1. All 4 (100%) patients had at least one symptom for which PRO-CTCAE suggested greater symptom burden than was reflected in CTCAE. Conclusions In this illustrative summary of a dose cohort, PRO-CTCAE complemented CTCAE reporting by capturing patient-reported symptomatic burden that was not always fully reflected by clinician-graded adverse events. Reviewing PRO-CTCAE and CTCAE data together during dose-cohort evaluation may enrich discussions on safety and tolerability in phase I trials.
// Source
Authors: Carolyn Mead‐Harvey, Brie N. Noble, Claire Yee, Gina L. Mazza, Blake Langlais, Sheetal Patel, Peter C. Trask, Lauren J. Rogak, Ethan Basch, Amylou Constance Dueck, Gita Thanarajasingam
Institutions: UNC Lineberger Comprehensive Cancer Center, Mayo Clinic in Arizona, Mayo Clinic, Genentech